startup

Lindis Biotech

Development of Triomab® antibodies - a new class of T-cell activating bispecific antibodies that enable the immune system to transform malignant cancers into treatable and potentially curable diseases.
  • Life Science & Healthcare
  • Steady Stage
  • Other
  • B2B
  • 2010
  • 1-10 Employees
  • Found
  • Planegg, DE
  • lindisbiotech.com
  • Lindis Biotech GmbH
  • Bayern

Profile is not claimed et

This profile is created by the Startbase Analyst Team. If you are a team member of this company you can claim the profile in order to make changes to it.

Is this your company? Claim profile

About the Team

Are you part of this team?

Management

Horst Lindhofer Geschäftsführer
since 2010

News about Lindis Biotech

Recent mentions of Lindis Biotech in podcasts & videos:

Jobs at Lindis Biotech:

Other Startups nearby

Bind-X
Startup 2013 Planegg
Bind-X
Industrial applications in the field of biotechnology.
SciRhom
Startup 2016 Planegg
SciRhom
Developing drugs to combat life-threatening diseases.
PreOmics
Startup 2016 Planegg
PreOmics
Develops and provides technologies for mass spectrometry-based proteomics.
Atriva Therapeutics
Startup 2015 Planegg
Atriva Therapeutics
Antiviral therapies against several severe respiratory viral infections with high unmet medical need, such as influenza and COVID-19.
adivo
Startup 2018 Planegg
adivo
Development of specific antibodies for veterinary medicine.

FYI: English edition available

Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?

Go to English edition

FYI: Deutsche Edition verfügbar

Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?

Deutsche Edition öffnen